诺华制药(NVS.US)20亿美元收购Excellergy 加码食物过敏与免疫疾病赛道

智通财经03-27

智通财经APP获悉，诺华制药(NVS.US)已同意以高达20亿美元的价格收购生物技术公司Excellergy Inc.，此项交易将强化其在食物过敏及其他免疫疾病治疗领域的产品组合。这家瑞士制药商在声明中表示，交易包含预付款及里程碑付款，预计将于今年下半年完成，但需满足包括监管部门批准在内的多项条件。此次收购的核心资产是Excellergy公司研发的创新候选药物Exl-111。作为一种新型的三功能...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2622845105?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-27 15:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622845105","market":"sh","top_or_hot":-1,"title":"诺华制药(NVS.US)20亿美元收购Excellergy 加码食物过敏与免疫疾病赛道","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，诺华制药(NVS.US)已同意以高达20亿美元的价格收购生物技术公司Excellergy Inc.，此项交易将强化其在食物过敏及其他免疫疾病治疗领域的产品组合。这家瑞士制药商在声明中表示，交易包含预付款及里程碑付款，预计将于今年下半年完成，但需满足包括监管部门批准在内的多项条件。此次收购的核心资产是Excellergy公司研发的创新候选药物Exl-111。作为一种新型的三功能...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1420347.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺华制药(NVS.US)20亿美元收购Excellergy 加码食物过敏与免疫疾病赛道</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺华制药(NVS.US)20亿美元收购Excellergy 加码食物过敏与免疫疾病赛道\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-27 15:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1420347.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，诺华制药(NVS.US)已同意以高达20亿美元的价格收购生物技术公司Excellergy Inc.，此项交易将强化其在食物过敏及其他免疫疾病治疗领域的产品组合。这家瑞士制药商在声明中表示，交易包含预付款及里程碑付款，预计将于今年下半年完成，但需满足包括监管部门批准在内的多项条件。此次收购的核心资产是Excellergy公司研发的创新候选药物Exl-111。作为一种新型的三功能...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1420347.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0070302665.USD","symbol_name":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1420347.html","article_id":"2622845105","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622845105","pubTimestamp":1774597007,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，诺华制药已同意以高达20亿美元的价格收购生物技术公司Excellergy Inc.，此项交易将强化其在食物过敏及其他免疫疾病治疗领域的产品组合。此次收购的核心资产是Excellergy公司研发的创新候选药物Exl-111。从行业影响来看，Excellergy的加入将使诺华制药在过敏性疾病领域拥有更具差异化的产品组合。此外，诺华制药还于去年10月宣布了其最大规模投资之一——以120亿美元收购Avidity Biosciences公司，随后又陆续达成多项针对过敏性疾病及乳腺癌药物的交易合作。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","01477":"欧康维视生物-B","BK4578":"CAR-T","NVS":"诺华","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4588":"碎股","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4007":"制药","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK1191":"制药","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4532":"文艺复兴科技持仓","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC"},"translate_title":"Novartis Pharmaceuticals (NVS.US) acquires Excellergy for $2 billion to increase food allergy and immune disease track","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":1.5,"01477":1.5},"content_text":"智通财经APP获悉，诺华制药(NVS.US)已同意以高达20亿美元的价格收购生物技术公司Excellergy Inc.，此项交易将强化其在食物过敏及其他免疫疾病治疗领域的产品组合。这家瑞士制药商在声明中表示，交易包含预付款及里程碑付款，预计将于今年下半年完成，但需满足包括监管部门批准在内的多项条件。此次收购的核心资产是Excellergy公司研发的创新候选药物Exl-111。作为一种新型的三功能效应细胞反应抑制剂(ECRI)，Exl-111主要针对IgE(免疫球蛋白E)介导的免疫通路。据了解，IgE是治疗多种过敏性疾病的关键因素，它会引发人体对原本无害物质产生过度反应。与现有的抗IgE疗法相比，该候选药物在设计上具备更强效的信号抑制能力，能够更迅速且深层地阻断过敏反应。目前，Exl-111正处于早期临床试验阶段，据公司介绍，该药物有望成为治疗食物过敏、慢性自发性荨麻疹、慢性诱发性荨麻疹和过敏性哮喘等多种疾病的潜在方案。从行业影响来看，Excellergy的加入将使诺华制药在过敏性疾病领域拥有更具差异化的产品组合。随着全球过敏性疾病发病率的持续上升，市场对更长效、更安全的生物制剂需求日益迫切。Exl-111若能顺利进入后期临床并获批上市，将与诺华制药现有的免疫管线产生协同效应。值得一提的是，近年来，因多款畅销老药持续面临仿制药竞争，诺华制药正通过密集收购强化其研发管线，这也导致其预计将出现至少六年来的首次利润下滑。就在此项交易达成的一周前，诺华制药刚刚宣布以30亿美元的价格将Synnovation Therapeutics收入囊中，以强化其在肿瘤领域的资产储备。此外，诺华制药还于去年10月宣布了其最大规模投资之一——以120亿美元收购Avidity Biosciences公司，随后又陆续达成多项针对过敏性疾病及乳腺癌药物的交易合作。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622845105","isCrawlerRequest":true}